DLL4 and non-small cell lung carcinoma: For the most investigated example, Demcizumab is a humanized anti-DLL4 IgG2 mAb, whose antitumor efficacy in combination with specific first-line antitumor drugs has been tested on PDAC and non-small cell lung cancer (NSCLC) respectively in various phase I/II trials [103,104].